title: Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis.
abstract: OBJECTIVE
  The purpose of the study is to evaluate in a double-blind, randomized study the efficacy of lodoxamide tromethamine 0.1% versus placebo.
  
  
  METHODS
  Signs and symptoms, tear tryptase, and tear fluid cytology were evaluated in 20 asymptomatic subjects with allergic conjunctivitis. The study included three allergen challenges in skin test-positive patients. At the first visit, a threshold dose of allergen was established. At the second visit, a bilateral ocular challenge was performed without pretreatment. At the third visit, either lodoxamide or placebo eye drops were used for 1 week before ocular challenge.
  
  
  RESULTS
  Lodoxamide significantly reduced tryptase levels (P < 0.01), neutrophils (P < 0.04), and eosinophils (P < 0.01) in the tear fluid and significantly inhibited ocular itching (P < 0.02) when compared with that of placebo.
  
  
  CONCLUSIONS
  Lodoxamide is effective in reducing tryptase levels and the recruitment of inflammatory cells in the tear fluid after allergen challenge.
authors.affiliation: Department of Opthalmology, University of Rome Tor Vergata, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Bonini
authors.forename: M
authors.initials: M
authors.lastname: Schiavone
authors.forename: S
authors.initials: S
authors.lastname: Bonini
authors.forename: L
authors.initials: L
authors.lastname: Magrini
authors.forename: P
authors.initials: P
authors.lastname: Lischetti
authors.forename: A
authors.initials: A
authors.lastname: Lambiase
authors.forename: M G
authors.initials: MG
authors.lastname: Bucci
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000485:Allergens / Q000008:administration & dosage / Q000276:immunology*; D002648:Child; D053818:Chymases; D003228:Conjunctiva / Q000276:immunology*; D003233:Conjunctivitis, Allergic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D004311:Double-Blind Method; D004804:Eosinophils / Q000187:drug effects*; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D008129:Lolium / Q000276:immunology; D008297:Male; D008407:Mast Cells / Q000187:drug effects*; D009570:Nitriles; D009883:Ophthalmic Solutions; D010072:Oxamic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011852:Radioallergosorbent Test / Q000379:methods; D015203:Reproducibility of Results; D012697:Serine Endopeptidases / Q000378:metabolism; D012882:Skin Tests; D013666:Tears / Q000166:cytology / Q000201:enzymology / Q000276:immunology; D016896:Treatment Outcome; D014325:Tromethamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D053802:Tryptases
chemical_list: D000485:Allergens; D006634:Histamine H1 Antagonists; D018836:Inflammation Mediators; D009570:Nitriles; D009883:Ophthalmic Solutions; D014325:Tromethamine; C022028:lodoxamide tromethamine; D012697:Serine Endopeptidases; C083294:chymase 2; D053818:Chymases; D053802:Tryptases; D010072:Oxamic Acid